Department of General, Visceral and Vascular Surgery, University Hospital Jena, Erlanger Allee 101, Jena, Germany.
Transpl Int. 2011 Sep;24(9):904-11. doi: 10.1111/j.1432-2277.2011.01283.x. Epub 2011 Jun 11.
The aim of this analysis was to provide an update on the current trend in living donor liver transplantation (LDLT) for adult recipients in the model of end stage liver disease (MELD) era in Germany and to encourage a wider implementation of LDLT. We descriptively analysed the data of LDLTs in Germany from 15 December 2006 to 31 December 2009 using a multi-center retrospective analysis via a questionnaire and data provided by Eurotransplant. Ten German centers performed LDLTs in adults. Eighty four transplantations in 50 male recipients and 34 female recipients were performed during the review period, ranging from 1 to 16 LDLTs per center. Hepatocellular carcinoma in cirrhosis (15/84) was the most common transplantation indication. The recipient mean lab-MELD score was 15 (±8). Six re-transplantations were necessary after initial LDLTs. The 1-year patient survival was 81%. We obtained data of 79/84 donors. The incidence of complications was 30.4% (n = 24). There were no grade 5 complications according to the Clavien classification. LDLT is an established treatment option that may reduce the waiting time, provides high quality split liver grafts and should be advocated in the MELD era to reduce organ shortage and 'death on the waiting list'.
本分析旨在提供德国终末期肝病模型(MELD)时代成人活体供肝移植(LDLT)现状的最新趋势,并鼓励更广泛地开展 LDLT。我们通过问卷调查和 Eurotransplant 提供的数据,对德国 2006 年 12 月 15 日至 2009 年 12 月 31 日期间的 LDLT 数据进行了描述性分析。10 家德国中心对成人进行了 LDLT。在审查期间,50 名男性受者和 34 名女性受者共进行了 84 例移植,每个中心进行了 1 至 16 例 LDLT。肝硬化肝细胞癌(15/84)是最常见的移植适应证。受者平均实验室-MELD 评分为 15(±8)。初始 LDLT 后有 6 例需要再次移植。1 年患者存活率为 81%。我们获得了 79/84 例供者的数据。并发症发生率为 30.4%(n=24)。根据 Clavien 分类,没有 5 级并发症。LDLT 是一种成熟的治疗选择,可缩短等待时间,提供高质量的分体肝移植物,应在 MELD 时代倡导,以减少器官短缺和“等待名单上的死亡”。